Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multispecific antiviral T-cell therapy for chemo-refractory viral infections after allogeneic HSCT
2018-000853-29Phase 3Active
- Sponsor
- LMU Klinikum
- Start
- Jun 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of HLA-matched multivirus-specific T cells in cytomegalovirus disease (CMV), Epstein-Barr virus infection and adenoviral infection, sponsored by LMU Klinikum. Primary endpoint: Viral clearance. Started Jun 2019; status: active.
02
Drugs
HLA-matched multivirus-specific T cells
03
Conditions
cytomegalovirus disease (CMV)Epstein-Barr virus infectionadenoviral infection
Beyond the preview
Go deeper on 2018-000853-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000853-29.